NSD2 and colorectal carcinoma: In a study done by Zhao et al. in 2021, CRISPR/Cas9 targeted KO of nuclear receptor-binding SET domain protein 2 (NSD2) inhibited not only the viability, proliferation, migration, and invasion of CRC cells but also inhibited the growth of CRC in the mouse model [88].